Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

No effective therapeutics or vaccines are available against Middle East Respiratory Syndrome Coronavirus (MERS-CoV). This technology is for human antibodies targeting MERS-CoV. Certain of these antibodies bind with epitopes of the MERS-CoV receptor binding domain (RBD) of MERS-CoV spike (S) protein with high affinity and are capable of neutralized the virus in a pseudovirus assay. The MERS-CoV-S protein is believed to be required for binding and virus entry during MERS-CoV infection. The human to human aspect of transmission and the high mortality rate associated with MERS-CoV infection have raised concerns over the potential for a future MERS-CoV pandemic and emphasized the need for development of effective therapeutics and vaccines. The antibodies of this technology represent candidate antibody-based therapeutics for treatment of MERS-CoV infection.

Potential Commercial Applications: Competitive Advantages:
  • Antibody-based therapeutics for treatment of MERS-CoV infection.
  • No vaccine or other biologic therapy is available
  • High binding (sub-nanomolar) affinity
  • Relative safety and long half-lives

Dimiter Dimitrov (NCI)
Tianlei Ying (NCI)
Tina Yu (NCI)
Kwok Yuen

Intellectual Property:
US Application No. 61/892,750

Zaki AM, et al. PMID 23075143
Zhu Z, et al. PMID 18271743
Zhu Z, et al. PMID 17620608

Collaboration Opportunity:

The National Cancer Institute, Cancer and Inflammation Program, Laboratory of Experimental Immunology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize animal studies, cGMP Manufacturing, clinical trials. For collaboration opportunities, please contact John D. Hewes, Ph.D. at To view the NCI collaborative opportunity announcement, click here.

Licensing Contact:
Edward (Tedd) Fenn , J.D.
NIH Office of Technology Transfer
Phone: 301-435-5031

OTT Reference No: E-002-2014/0

Updated: Apr-15-2014